|
Market Closed -
Nasdaq
16:00:00 2026-09-03 EDT
|
5-day change | 1st Jan Change | ||
| 128.00 USD | -0.64% |
|
+0.20% | +29.59% |
| 08-31 | Incyte Corporation Enters Agreement with U.S. Centers for Medicare & Medicaid Services | CI |
| 08-28 | US FDA approves Takeda, Protagonist's drug for rare blood cancer | RE |
Company Valuation: Incyte Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 16,213 | 17,869 | 14,072 | 13,306 | 19,391 | 25,945 | - | - |
| Change | - | 10.21% | -21.25% | -5.44% | 45.73% | 33.8% | - | - |
| Enterprise Value (EV) 1 | 13,865 | 14,630 | 10,416 | 11,148 | 16,293 | 21,716 | 19,954 | 17,975 |
| Change | - | 5.52% | -28.81% | 7.03% | 46.15% | 33.28% | -8.11% | -9.92% |
| P/E | 17.2x | 52.8x | 23.7x | 460x | 15.4x | 57.1x | 17.7x | 16.3x |
| PBR | 4.32x | 4.09x | 2.71x | 3.88x | 3.79x | 4.37x | 3.3x | 2.6x |
| PEG | - | -0.8x | 0.3x | -4.9x | 0x | -0.9x | 0x | 1.9x |
| Capitalization / Revenue | 5.43x | 5.26x | 3.81x | 3.14x | 3.77x | 4.37x | 4.14x | 3.95x |
| EV / Revenue | 4.64x | 4.31x | 2.82x | 2.63x | 3.17x | 3.65x | 3.19x | 2.74x |
| EV / EBITDA | 21.5x | 24.5x | 14.8x | 22.2x | 9.53x | 28.3x | 9.38x | 9x |
| EV / EBIT | 23.7x | 25.2x | 16.8x | 26.9x | 10.1x | 25.1x | 8.77x | 7.08x |
| EV / FCF | 24.4x | 16.4x | 22.4x | 44.8x | - | 32.1x | 12.2x | 10.3x |
| FCF Yield | 4.1% | 6.1% | 4.45% | 2.23% | - | 3.11% | 8.18% | 9.73% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 4.27 | 1.52 | 2.65 | 0.15 | 6.41 | 2.241 | 7.239 | 7.859 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 2,986 | 3,395 | 3,696 | 4,241 | 5,141 | 5,942 | 6,265 | 6,566 |
| EBITDA 1 | 643.6 | 597.7 | 703.2 | 503.1 | 1,709 | 766.9 | 2,126 | 1,996 |
| EBIT 1 | 585.8 | 579.4 | 620.5 | 413.9 | 1,616 | 863.9 | 2,276 | 2,540 |
| Net income 1 | 948.6 | 340.7 | 597.6 | 32.62 | 1,287 | 465.8 | 1,496 | 1,696 |
| Net Debt 1 | -2,348 | -3,239 | -3,656 | -2,158 | -3,098 | -4,230 | -5,991 | -7,970 |
| Reference price 2 | 73.40 | 80.32 | 62.79 | 69.07 | 98.77 | 128.00 | 128.00 | 128.00 |
| Nbr of stocks (in thousands) | 220,891 | 222,475 | 224,109 | 192,650 | 196,323 | 202,698 | - | - |
| Announcement Date | 2/8/22 | 2/7/23 | 2/13/24 | 2/10/25 | 2/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 57.12x | 3.65x | 28.32x | -.--% | 25.95B | |
| 19.53x | 4.57x | 10.77x | 0.46% | 84.22B | |
| -17.71x | 26.55x | -17.53x | -.--% | 59.43B | |
| 20.65x | 4.41x | 13.65x | 2.37% | 60.48B | |
| 35.98x | 12.26x | 23.5x | -.--% | 50.31B | |
| 22.03x | 4.87x | 13.88x | 0.66% | 48.91B | |
| 39.89x | 3.65x | 13.91x | -.--% | 33.17B | |
| 68.4x | 7.28x | 44.26x | -.--% | 22.78B | |
| 24.11x | 5.15x | 13.42x | -.--% | 16.73B | |
| 66.16x | 40.88x | 58.63x | 0.17% | 14.52B | |
| Average | 33.62x | 11.33x | 20.28x | 0.37% | 41.65B | |
| Weighted average by Cap. | 25.11x | 9.95x | 14.00x | 0.52% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- INCY Stock
- Valuation Incyte Corporation
Select your edition
All financial news and data tailored to specific country editions
